Dasdemir Ilkhan Gulay, Demirci Üçsular Fatma, Celikhisar Hakan, Arman Yücel, Yalnız Enver, Tükek Tufan
Department of Chest Diseases, Tire State Hospital, Izmir-Turkey.
Health Sciences University, Dr. Chest Diseases and Thoracic Surgery Training and Research Hospital, Chest Diseases Hospital, Izmir-Turkey.
Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(2):e2021020. doi: 10.36141/svdld.v38i2.10623. Epub 2021 Jun 28.
In this study, we aimed to investigate the possible role of endotrophin, a profibrotic byproduct of collagen VI, in the complex process of fibrosis development in the disease group with pulmonary fibrosis among interstitial lung diseases.
When the patients' participation in the study were completed, smoking or alcohol drinking conditions, and family history were recorded. Their weights and heights were recorded and body mass index (BMI) was calculated. In every patient, Spirometry with bronchodilator testing, determination of single-breath DLCO, and plethysmographic measurement of thoracic gas volume and airway resistance were performed. Blood samples were obtained for the inflammation markers such as sedimentation rate, C-reactive protein (CRP), complete blood count, liver and renal function tests, and lactate dehydrogenase levels. Serum endotrophin levels were measured in all patients.
Thirty-five patients with interstitial lung disease who were having pulmonary fibrosis, 35 patients with interstitial lung disease without pulmonary fibrosis, and 20 control patients without any signs or symptoms of interstitial lung disease were included in the study. Age distribution was similar between groups. The fibrotic ILD group was more commonly smoker or ex-smoker compared with the non-fibrotic ILD patients or control cases. Fibrotic ILD patients were leaner, having significantly decreased total lung capacity, diffusion capacity, and higher LDH levels. In the comparison of the 3 study groups regarding the endotrophin levels, there was a significant difference between groups. The fibrotic and non-fibrotic patient groups were compared for the Endotrophin levels and the difference was also significant. However, there was not any significant difference regarding the endotrophin levels between control cases and non-fibrotic ILD patients. Smoked cigarette pocket x year showed a significant positive correlation and DLCO % and KCO % showed a significant negative correlation with the endotrophin levels.
Serum endotrophin levels significantly increase in fibrotic ILD patients compared with the non-fibrotic ILD patients and control cases. Endotrophin may be suggested as a diagnostic marker in fibrotic interstitial lung diseases.
在本研究中,我们旨在探讨内营养蛋白(一种VI型胶原蛋白的促纤维化副产物)在间质性肺疾病中肺纤维化疾病组纤维化发展的复杂过程中可能发挥的作用。
在患者完成参与研究后,记录其吸烟或饮酒情况以及家族史。记录他们的体重和身高并计算体重指数(BMI)。对每位患者进行支气管扩张剂测试的肺功能测定、单次呼吸一氧化碳弥散量(DLCO)测定以及胸廓气体容积和气道阻力的体积描记法测量。采集血样以检测炎症标志物,如血沉、C反应蛋白(CRP)、全血细胞计数、肝肾功能测试以及乳酸脱氢酶水平。测定所有患者的血清内营养蛋白水平。
本研究纳入了35例患有肺纤维化的间质性肺疾病患者、35例无肺纤维化的间质性肺疾病患者以及20例无任何间质性肺疾病体征或症状的对照患者。各组间年龄分布相似。与非纤维化ILD患者或对照病例相比,纤维化ILD组更常见吸烟者或既往吸烟者。纤维化ILD患者体型更瘦,总肺容量、弥散能力显著降低,乳酸脱氢酶水平更高。在比较3个研究组的内营养蛋白水平时,组间存在显著差异。比较纤维化和非纤维化患者组的内营养蛋白水平,差异也显著。然而,对照病例与非纤维化ILD患者之间的内营养蛋白水平无显著差异。吸烟包年数与内营养蛋白水平呈显著正相关,DLCO%和KCO%与内营养蛋白水平呈显著负相关。
与非纤维化ILD患者和对照病例相比,纤维化ILD患者的血清内营养蛋白水平显著升高。内营养蛋白可被建议作为纤维化间质性肺疾病的诊断标志物。